Septerna Marge brute

Que fait Septerna ? Septerna, Inc. develops oral small molecule GPCR-targeted drugs using its proprietary Native Complex PlatformTM. The company focuses on endocrinology, immunology, and inflammation, and metabolic diseases. Its pipeline targets GPCRs for the first time, uncovering novel binding pockets and pursuing various pharmacologies like agonists and antagonists. The firm advances a deep portfolio of programs for patients with significant unmet needs. Septerna's products are developed for pharmaceutical companies seeking novel drug discovery platforms. The company's Native Complex PlatformTM enables industrial-scale GPCR targeting, offering solutions for diseases with high unmet medical needs. Its therapeutic areas include endocrinology, immunology, and inflammation, and metabolic diseases, targeting patients requiring innovative treatments. The company's pipeline includes oral small molecule drug candidates for GPCR-targeted therapies. These candidates are designed to address conditions in endocrinology, immunology, and inflammation, and metabolic diseases. Septerna's approach focuses on uncovering novel binding pockets and pursuing diverse pharmacologies to achieve therapeutic effects. The firm's programs target patients with significant unmet needs across multiple therapeutic areas. Septerna est l'une des entreprises les plus populaires sur Eulerpool.